Study Evaluating Multiple Doses Of ATN-103 In Subjects Wi... | NCT00959036 | Trialant

Study Evaluating Multiple Doses Of ATN-103 In Subjects Wi... | NCT00959036 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Treatment Group 1	Experimental	ATN-103 10 mg every 4 weeks until week 12	Drug: ATN-103 Drug: Methotrexate
Treatment Group 2	Experimental	ATN-103 10 mg every 8 weeks until week 12	Drug: ATN-103 Drug: Methotrexate
Treatment Group 3	Experimental	ATN-103 30 mg every 4 weeks until week 12	Drug: ATN-103 Drug: Methotrexate
Treatment Group 4	Experimental	ATN-103 80 mg every 4 weeks until week 12	Drug: ATN-103 Drug: Methotrexate
Treatment Group 5	Experimental	ATN-103 80 mg every 8 weeks until week 12	Drug: ATN-103 Drug: Methotrexate
Treatment Group 6	Placebo Comparator	Placebo every 4 weeks

Outcomes Module

Secondary Outcomes

Measure	Description	Time Frame
Additional efficacy endpoints as measured by the number of swollen and tender joints, physician and patient global assessments of disease activity, ACR responses, DAS28, EULAR, and Health Outcome Assessments		6 months

Contacts/Locations Module